Has Shawn Sabin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,783 in general payments to Shawn Sabin, MD across 198 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shawn Sabin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shawn Sabin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shawn Sabin, MD

MOHS-Micrographic Surgery · Leawood, KSNPI 1427002575

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 198 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations.

$3,783in general payments, 2019–2025

Across 198 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$708
Novartis$303
Johnson & Johnson$280
UCB, Inc.$277
Regeneron Healthcare Solutions, Inc.$259
Sun Pharmaceutical Industries Inc.$246
plus $2K from 25 others

What the payments were for

Food & beverage$3,783100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	45	$708
Novartis	14	$303
Johnson & Johnson	21	$280
UCB, Inc.	12	$277
Regeneron Healthcare Solutions, Inc.	9	$259
Sun Pharmaceutical Industries Inc.	15	$246
Kerecis Limited	9	$214
Almirall LLC	6	$156
Genentech USA, Inc.	10	$149
Convatec Inc.	6	$147
Lilly USA, LLC	7	$143
Bristol Myers Squibb	2	$127
Galderma Laboratories, L.p.	3	$106
Amgen	4	$79
Ortho Dermatologics, A Division Of Bausch Health US, LLC	5	$71
Incyte Corporation	3	$64
LEO Pharma Inc.	4	$55
Boehringer Ingelheim	3	$49
Organon	2	$48
Urgo Medical North America, LLC	2	$45
Pfizer	2	$42
Organogenesis Inc.	2	$37
Sanofi	2	$36
Surgenex LLC	2	$33
Aclaris Therapeutics, Inc.	2	$32
Biofrontera Inc.	1	$16
Mallinckrodt Enterprises LLC	1	$15
Mayne Pharma Commercial LLC	1	$13
Merck	1	$11
Dermira, Inc.	1	$11
Journey Medical Corporation	1	$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Otezla$111
DUPIXENT$100

How this compares

Too few mohs-micrographic surgery providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$502,321

Medicare patients

588

Services billed

1,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Doxycycline Monohydrate	247	$2,258
Cephalexin	213	$1,158
Doxycycline Hyclate	143	$919
Ketoconazole	24	$408
Amoxicillin	38	$29

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Leawood

Mark FleischmanLeawood$23K
James GriffithLeawood$5K
Glenn GoldsteinLeawood$2K
Elizabeth SpenceriLeawood$2K
Joseph GadziaTopeka$28K
Majdy AlbahharManhattan$10K
Matthew ShafferSalina$8K
Kevin BroughWichita$8K
Jeanette PittsMission$940
Jesalyn TateKansas City$893

See the full list for Kansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →